Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 14/20 | 0.83 |
| ▸ | IMPDH1 | P20839 | 3/20 | 0.76 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1473366 | 0.91 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6495167 | 0.90 | IMPDH2 (0.79) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL14518602 | 0.90 | IMPDH2 (0.83) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1472764 | 0.88 | IMPDH2 (0.83) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL14518615 | 0.88 | IMPDH2 (0.74) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL3995894 | 0.88 | IMPDH2 (0.82) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL7549462 | 0.88 | IMPDH2 (0.85) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL15741615 | 0.87 | IMPDH2 (0.78) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL5531405 | 0.86 | AAK1 (0.75) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1474014 | 0.86 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009018344-A1 | ANTICANCER AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2009-02-05 | — | — | WO | disclosed |
| US-7205324-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205324-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205324-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1127054-A4 | NOVEL INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2006-11-02 | — | — | EP | disclosed |
| US-7060720-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB CO. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20060122245-A1 | Novel inhibitors of IMPDH enzyme | GU HENRY H | 2006-06-08 | — | — | US | disclosed |
| US-7053111-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB CO. (US) | 2006-05-30 | — | — | US | disclosed |
| US-6867299-B2 | Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents | HOFFMANN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-20040102497-A1 | Novel inhibitors of IMPDH enzyme | GU HENRY H (US) | 2004-05-27 | — | — | US | disclosed |
| US-20040082562-A1 | Novel inhibitors of IMPDH enzyme | GU HENRY H (US) | 2004-04-29 | — | — | US | disclosed |
| US-6624184-B1 | Identification of the inhibitors of IMPDH (inosine-5'-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH associated disorders, and | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020052513-A1 | Oxamide IMPDH inhibitors | HOFFMANN-LA ROCHE INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1127883-A2 | Oxamides as IMPDH inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-29 | — | — | EP | disclosed |
| EP-1127054-A1 | NOVEL INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000026197-A9 | NOVEL INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000026197-A1 | NOVEL INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122245-A1 | Novel inhibitors of IMPDH enzyme | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885IMPDH1 1/4885AAK1 1956/4885 |
| US-20040082562-A1 | Novel inhibitors of IMPDH enzyme | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885IMPDH1 1/4885AAK1 2009/4885 |
| US-20020052513-A1 | Oxamide IMPDH inhibitors | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885IMPDH1 1/4885AAK1 2882/4885 |
| US-20040102497-A1 | Novel inhibitors of IMPDH enzyme | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885IMPDH1 1/4885AAK1 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.